- Home
- DNUT vs OCS Comparison
DNUT vs OCS Comparison
Compare DNUT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- OCS
- Stock Information
- Founded
- DNUT 1937
- OCS 2003
- Country
- DNUT United States
- OCS Switzerland
- Employees
- DNUT 22800
- OCS N/A
- Industry
- DNUT Food Chains
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- OCS Health Care
- Exchange
- DNUT Nasdaq
- OCS Nasdaq
- Market Cap
- DNUT 509.0M
- OCS 689.8M
- IPO Year
- DNUT 2021
- OCS N/A
- Fundamental
- Price
- DNUT $2.88
- OCS $19.38
- Analyst Decision
- DNUT Buy
- OCS Strong Buy
- Analyst Count
- DNUT 8
- OCS 4
- Target Price
- DNUT $10.23
- OCS $31.50
- AVG Volume (30 Days)
- DNUT 7.2M
- OCS 29.0K
- Earning Date
- DNUT 05-08-2025
- OCS 05-08-2025
- Dividend Yield
- DNUT 4.84%
- OCS N/A
- EPS Growth
- DNUT N/A
- OCS N/A
- EPS
- DNUT N/A
- OCS N/A
- Revenue
- DNUT $1,597,883,000.00
- OCS $847,333.00
- Revenue This Year
- DNUT N/A
- OCS $53.79
- Revenue Next Year
- DNUT $3.61
- OCS $1,860.95
- P/E Ratio
- DNUT N/A
- OCS N/A
- Revenue Growth
- DNUT N/A
- OCS N/A
- 52 Week Low
- DNUT $2.58
- OCS $10.79
- 52 Week High
- DNUT $12.68
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- DNUT 31.79
- OCS 58.76
- Support Level
- DNUT $2.85
- OCS $19.35
- Resistance Level
- DNUT $3.08
- OCS $20.45
- Average True Range (ATR)
- DNUT 0.13
- OCS 0.74
- MACD
- DNUT 0.03
- OCS 0.17
- Stochastic Oscillator
- DNUT 8.70
- OCS 68.75
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.